Topotecan injection, solution, concentrate

Warning: myelosuppression

Topotecan can cause severe myelosuppression. Administer first cycle only to patients with baseline neutrophil counts of greater than or equal to 1,500/mm 3and platelet counts greater than or equal to 100,000/mm 3. Monitor blood cell counts [see Warnings and Precautions (5.1)].

WARNING: MYELOSUPPRESSION

See full prescribing information for complete boxed warning.

Topotecan can cause severe myelosuppression. Administer first cycle only to patients with baseline neutrophil counts greater than or equal to 1,500/mm 3and platelet count greater than or equal to 100,000/mm 3. Monitor blood cell counts. ( 2.2, 5.1)

1 indications and usage

Topotecan Injection is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy.

Topotecan Injection is a topoisomerase inhibitor indicated for treatment of small cell lung cancer (SCLC) platinum-sensitive disease in patients who progressed at least 60 days after initiation of first-line chemotherapy. ( 1)

2 dosage and administration

  • Recommended dosage: 1.5 mg/m 2by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day cycle. ( 2.2)
  • Renal impairment: Reduce dose for creatinine clearance (CLcr) of 20 to 39 mL/min. ( 2.4)

2.1 important safety information

Verify dosage using body surface area. Do not exceed a single dose of 4 mg intravenously.

2.2 recommended dosage for small cell lung cancer

The recommended dosage of Topotecan Injection is 1.5 mg/m 2by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day cycle.

2.3 dosage modifications for adverse reactions

Hematologic

Do not administer subsequent cycles of Topotecan Injection until neutrophils recover to greater than 1,000/mm 3, platelets recover to greater than 100,000/mm 3, and hemoglobin levels recover to greater than or equal to 9 g/dL (with transfusion if necessary).

Reduce the dose of Topotecan Injection to 1.25 mg/m 2/day for:

  • neutrophil counts of less than 500/mm 3or administer granulocyte-colony stimulating factor (G-CSF) starting no sooner than 24 hours following the last dose
  • platelet counts less than 25,000/mm 3during previous cycle

2.4 dosage modifications for renal impairment

Reduce the dose of Topotecan Injection to 0.75 mg/m 2/day for patients with creatinine clearance (CLcr) of 20 to 39mL/min (calculated with the Cockcroft-Gault method using ideal body weight) [see Clinical Pharmacology (12.3)].

2.5 preparation and administration

Topotecan Injection is a cytotoxic drug. Follow applicable special handling and disposable procedures. 1

Withdraw the appropriate volume from the vial and discard any unused portion.

Dilute Topotecan Injection in a minimum of 50 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP prior to administration. Infuse diluted Topotecan Injection over 30 minutes.

Store diluted Topotecan Injection at 20 and 25C (68 and 77F) in ambient lighting conditions for no more than 24 hours. Discard unused portion after 24 hours.

Visually inspect for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if particulate matter or discoloration is observed.

3 dosage forms and strengths

Injection: 4 mg/4 mL (1 mg/mL topotecan free base) clear, yellow to yellow-green solution in single-dose vial.

Injection: 4 mg/4 mL (1 mg/mL topotecan free base) solution in single-dose vial. ( 3)

4 contraindications

Topotecan Injection is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan. Reactions have included anaphylactoid reactions [see Adverse Reactions (6.2)].

History of severe hypersensitivity reactions to topotecan. ( 4)

5 warnings and precautions

  • Interstitial lung disease (ILD): Fatal cases have occurred. Permanently discontinue if ILD confirmed. ( 5.2)
  • Extravasation and tissue injury: Severe cases have occurred. If extravasation occurs, immediately stop administration and institute recommended management procedures. ( 5.3)
  • Embryo-fetal toxicity: Can cause fetal harm. Advise women of potential risk to the fetus. ( 5.4, 8.1, 8.3)

5.1 myelosuppression

Topotecan can cause severe myelosuppression.

Grade 4 neutropenia occurred in 78% of 879 patients, with a median duration of 7 days and was most common during Cycle 1 (58% of patients). Grade 4 neutropenia associated with infection occurred in 13% and febrile neutropenia occurred in 5%. Sepsis occurred in 4% and was fatal in 1%. Grade 4 thrombocytopenia occurred in 27%, with a median duration of 5 days. Grade 3 or 4 anemia occurred in 37% of patients.

Topotecan can cause fatal typhlitis (neutropenic enterocolitis). Consider the possibility of typhlitis in patients presenting with fever, neutropenia, and abdominal pain.

Administer the first cycle of Topotecan Injection only to patients with a baseline neutrophil count of greater than or equal to 1,500/mm 3and a platelet count greater than or equal to 100,000/mm 3. Monitor blood counts frequently during treatment. Withhold and reduce dose of Topotecan Injection based on neutrophil counts, platelet counts and hemoglobin levels [see Dosage and Administration (2.3)].

5.2 interstitial lung disease

Interstitial lung disease (ILD), including fatalities, has occurred with topotecan [see Adverse Reactions (6.2)]. Underlying risk factors include history of ILD, pulmonary fibrosis, lung cancer, thoracic radiation, and use of pneumotoxic drugs and/or colony stimulating factors. Monitor patients for pulmonary symptoms indicative of ILD (e.g., cough, fever, dyspnea, and/or hypoxia), and discontinue Topotecan Injection if a new diagnosis of ILD is confirmed.

5.3 extravasation and tissue injury

Extravasation with topotecan has been observed; severe cases have been reported. If signs or symptoms of extravasation occur, immediately stop administration of Topotecan Injection and institute recommended management procedures [see Adverse Reactions (6.2)].

5.4 embryo-fetal toxicity

Based on animal data, topotecan can cause fetal harm when administered to a pregnant woman.

Topotecan caused embryolethality, fetotoxicity, and teratogenicity in rats and rabbits when administered during organogenesis. Advise women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 6 months after the last dose of Topotecan Injection. Advise males with a female partner of reproductive potential to use effective contraception during treatment with Topotecan Injection and for 3 months after the last dose [see Use in Specific Populations (8.1, 8.3), Nonclinical Toxicology (13.1)].

6 adverse reactions

The following serious adverse reactions are described elsewhere in the labeling:

  • The most common Grade 3 or 4 hematologic adverse reactions (incidence >5%) were: neutropenia, anemia, thrombocytopenia, and febrile neutropenia. ( 6.1)
  • The most common non-hematologic adverse reactions (incidence >5%) (all grades) were asthenia, dyspnea, nausea, pneumonia, abdominal pain, and fatigue. ( 6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 clinical trials experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data in Warnings and Precautions reflect exposure to topotecan from 8 trials in which 879 patients with small cell lung cancer (SCLC) and other solid tumors received topotecan 1.5mg/m 2by intravenous infusion daily for 5 consecutive days, starting on Day 1 of a 21-day cycle.

Small Cell Lung Cancer (SCLC)

The safety of topotecan was evaluated in randomized, comparative trial in patients with recurrent or progressive SCLC (Study 090) [see Clinical Studies (14.1)].Table 1 shows the Grade 3 or 4 hematologic and non-hematologic adverse reactions in patients with SCLC.

Table 1.

Adverse Reactions Occurring in 5% of Patients with Small Cell Lung Cancer in Study 090

Grade 3 to 4 (%)Grade 3 to 4 (%)DyspneaPneumoniaAstheniaFatiguePain aNauseaAbdominal painSepsis b

Adverse Reactions

Topotecan
(n = 107)

CAV C
(n = 104)

Hematologic

Grade 4 neutropenia (<500/mm 3)

70

72

Grade 3 or 4 anemia (Hgb < 8 g/dL)

42

20

Grade 4 thrombocytopenia (<25,000/mm 3)

29

5

Febrile neutropenia

28

26

Non-Hematologic

Respiratory, thoracic, and mediastinal

9

14

8

6

General and administrative site conditions

9

7

6

10

5

7

Gastrointestinal

8

6

6

4

Infections

5

5

  1. aPain includes body pain, skeletal pain, and back pain.
  2. bDeath related to sepsis occurred in 3% of patients receiving topotecan and 1% of patients receiving CAV.
  3. cCAV = cyclophosphamide, doxorubicin and vincristine.

Hepatobiliary Disorders

Based on 879 patients with small cell lung cancer or another solid tumor who were treated with topotecan, Grade 3 or 4 elevated aspartate (AST) or alanine transaminase (ALT) occurred in 4% and Grade 3 or 4 elevated bilirubin occurred in less than 2% of patients.

6.2 postmarketing experience

The following reactions have been identified during postapproval use of topotecan. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and Lymphatic System

Severe bleeding (in association with thrombocytopenia)

Hypersensitivity

Allergic manifestations, anaphylactoid reactions, angioedema

Gastrointestinal

Abdominal pain potentially associated with neutropenic enterocolitis, gastrointestinal perforation

Pulmonary

Interstitial lung disease

Skin and Subcutaneous Tissue

Severe dermatitis, severe pruritus

General and Administration Site Conditions

Extravasation, mucosal inflammation

8 use in specific populations

Lactation: Advise not to breastfeed. ( 8.2)

8.1 pregnancy

Risk Summary

Based on animal data and its mechanism of action, Topotecan Injection can cause fetal harm when administered to a pregnant woman. There are no available clinical data on the use of topotecan in pregnancy. Topotecan caused embryolethality, fetotoxicity, and teratogenicity in rats and rabbits when administered during organogenesis at doses similar to the clinical dose (see Data).Advise pregnant women of the potential risk to a fetus.

In the U.S. general population, the background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.

Data

Animal Data

In rabbits, an intravenous dose of 0.10 mg/kg/day [(about equal to the 1.5 mg/m 2clinical dose based on body surface area (BSA)] given on Days 6 through 20 of gestation caused maternal toxicity, embryolethality, and reduced fetal body weight. In the rat, an intravenous dose of 0.23 mg/kg/day (about equal to the 1.5 mg/m 2clinical dose based on BSA) given for 14 days before mating through gestation Day 6 caused fetal resorption, microphthalmia, pre-implant loss, and mild maternal toxicity.

Administration of an intravenous dose of 0.10 mg/kg/day (about half the 1.5 mg/m 2clinical dose based on BSA) given to rats on Days 6 through 17 of gestation caused an increase in post-implantation mortality. This dose also caused an increase in total fetal malformations. The most frequent malformations were of the eye (microphthalmia, anophthalmia, rosette formation of the retina, coloboma of the retina, ectopic orbit), brain (dilated lateral and third ventricles), skull, and vertebrae.

8.2 lactation

Risk Summary

There are no data on the presence of topotecan or its metabolites in human milk or their effects on the breastfed infant or on milk production. Lactating rats excrete high concentrations of topotecan in milk (see Data).Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with Topotecan Injection and for 1 week after the last dose.

Data

Following intravenous administration of topotecan to lactating rats at a dose of 4.72 mg/m 2(about twice the 1.5 mg/m 2clinical dose based on BSA), topotecan was excreted into milk at concentrations up to 48-fold higher than those in plasma.

8.3 females and males of reproductive potential

Pregnancy Testing

Verify pregnancy status of females of reproductive potential prior to initiating Topotecan Injection [see Use in Specific Populations (8.1)].

Contraception

Topotecan can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].

Females

Advise female patients of reproductive potential to use effective contraception during treatment with Topotecan Injection and for 6 months after the last dose.

Males

Topotecan may damage spermatozoa, resulting in possible genetic and fetal abnormalities. Advise males with a female partner of reproductive potential to use effective contraception during treatment with Topotecan Injection and for 3 months after the last dose [see Nonclinical Toxicology (13.1)].

Infertility

Females

Topotecan may have both acute and long-term effects on fertility [see Nonclinical Toxicology (13.1)].

Males

Effects on spermatogenesis occurred in animals administered topotecan [see Nonclinical Toxicology (13.1)].

8.4 pediatric use

Safety and effectiveness in pediatric patients have not been established.

8.5 geriatric use

Of the 879 patients with SCLC or another solid tumor who received topotecan in clinical trials, 32% were aged 65 years and older, while 3.8% were aged 75 years and older. No overall differences in effectiveness or safety were observed between these patients and younger patients and other reported clinical experience has not identified differences in responses between the elderly and younger patients.

8.6 renal impairment

Reduce the dose of Topotecan Injection for patients with a CLcr of 20 to 39 mL/min [see Dosage and Administration (2.4), Clinical Pharmacology (12.3)]. No dosage adjustment is recommended for patients with CLcr greater than or equal to 40mL/min. Insufficient data are available in patients with CLcr less than 20 mL/min to provide a dosage recommendation for Topotecan Injection.

10 overdosage

Overdoses (up to 10-fold of the recommended dose) have occurred in patients receiving intravenous topotecan. The primary complication of overdosage is myelosuppression. Elevated hepatic enzymes, mucositis, gastrointestinal toxicity and skin toxicity have occurred with overdosages. If an overdose is suspected, monitor the patient closely for myelosuppression and institute supportive-care measures as appropriate.

11 description

Topotecan is a semi-synthetic derivative of camptothecin and a topoisomerase inhibitor. The chemical name for topotecan hydrochloride is (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1 H-pyrano[3,4:6,7]indolizino[1,2- b]quinoline-3,14-(4 H,12 H)-dione 1.25 hydrochloride. It has the molecular formula C 23H 23N 3O 51.25 HCl and a molecular weight of 467.02. It is soluble in water and melts with decomposition at 213C to 218C.

Topotecan hydrochloride has the following structural formula:

Structure

Topotecan Injection for intravenous use is supplied as a sterile, non-pyrogenic, clear, yellow to yellow-green solution in single-dose vial at a topotecan free base concentration of 4 mg/4 mL (1mg/mL).

Each mL contains 1 mg topotecan free base (equivalent to 1.11mg of topotecan hydrochloride), 5mg tartaric acid, NF and water for injection, USP. It may also contain hydrochloric acid and/or sodium hydroxide to adjust the pH. The solution pH ranges from 2.6 to 3.2.

12 clinical pharmacology

12.1 mechanism of action

Topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents re-ligation of these single-strand breaks. The cytotoxicity of topotecan is thought to be due to double-strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair these double-strand breaks.

12.3 pharmacokinetics

Following administration of topotecan at doses of 0.5 to 1.5mg/m 2(0.3 to 1 times the recommended dose) administered as a 30-minute infusion, area under the curve (AUC) increases approximately proportional with dose.

Distribution

Protein binding of topotecan is approximately 35%.

Elimination

The terminal half-life of topotecan is 2 to 3 hours following intravenous administration.

Metabolism

Topotecan undergoes a reversible pH-dependent hydrolysis of its pharmacologically active lactone moiety. At pH 4, the lactone is exclusively present, whereas the ring-opened hydroxy-acid form predominates at physiologic pH. Topotecan is metabolized to an N-demethylated metabolite invitro. The mean metabolite: parent AUC ratio was about 3% for total topotecan and topotecan lactone following intravenous administration.

Excretion

The overall recovery of total topotecan and its N-desmethyl metabolite in urine and feces over 9 days averaged 73% 2% following an intravenous dose. Mean values of 51% 3% as total topotecan and 3% 1% as N-desmethyl topotecan were excreted in the urine. Fecal elimination of total topotecan accounted for 18% 4% while fecal elimination of N-desmethyl topotecan was 1.7% 0.6%. An O-glucuronidation metabolite of topotecan and N-desmethyl topotecan has been identified in the urine.

Specific Populations

No clinically significant differences in the pharmacokinetics of topotecan were observed based on age, sex, or hepatic impairment following intravenous administration.

Patients with Renal Impairment

Compared to patients with CLcr >60 mL/min (calculated by the Cockcroft-Gault method using ideal body weight), plasma clearance of topotecan lactone decreased by 33% in patients with CLcr 40 to 60 mL/min and decreased by 65% in patients with CLcr 20 to 39 mL/min. The effect on topotecan pharmacokinetics in patients with CLcr <20 mL/min is unknown [see Dosage and Administration (2.4)].

Drug Interaction Studies

Clinical Studies

No clinically significant changes in topotecan pharmacokinetics were observed when coadministered cisplatin.

No clinically significant changes in the pharmacokinetics of free platinum were observed in patients coadministered cisplatin with topotecan.

In Vitro Studies

Topotecan does not inhibit CYP1A2, CYP2A6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E, CYP3A, or CYP4A or dihydropyrimidine dehydrogenase.

13 nonclinical toxicology

13.1 carcinogenesis, mutagenesis, impairment of fertility

Carcinogenicity testing of topotecan has not been performed. Topotecan is known to be genotoxic to mammalian cells and is a probable carcinogen. Topotecan was mutagenic to L5178Y mouse lymphoma cells and clastogenic to cultured human lymphocytes with and without metabolic activation. It was also clastogenic to mouse bone marrow. Topotecan did not cause mutations in bacterial cells.

Topotecan given to female rats prior to mating at an intravenous dose of 1.4 mg/m 2(about equal to the 1.5 mg/m 2clinical dose based on BSA) caused superovulation possibly related to inhibition of follicular atresia. This dose given to pregnant female rats also caused increased pre-implantation loss. A one month study in dogs given a daily intravenous topotecan dose of 0.4mg/m 2(about 0.25 times the 1.5 mg/m 2clinical dose based on BSA) suggests that treatment may cause an increase in the incidence of multinucleated spermatogonial giant cells in the testes.

14 clinical studies

14.1 small cell lung cancer

The efficacy of topotecan was studied in 426 patients with recurrent or progressive SCLC in a randomized, comparative trial and in 3 single-arm trials.

Randomized Comparative Trial

In a randomized, comparative trial, 211 patients were randomized 1:1 to received topotecan (1.5 mg/m 2once daily intravenously for 5 days starting on Day 1 of a 21-day cycle) or CAV (cyclophosphamide 1,000 mg/m 2, doxorubicin 45 mg/m 2, vincristine 2 mg administered sequentially on Day 1 of a 21-day cycle). All patients were considered sensitive to first-line chemotherapy (responders who then subsequently progressed greater than or equal to 60 days after completion of first-line therapy). A total of 77% of patients treated with topotecan and 79% of patients treated with CAV received platinum/etoposide with or without other agents as first-line chemotherapy. The efficacy outcome measures were overall response rate, response duration, time to progression and overall survival (OS).

The results of the trial did not show statistically significant improvements in response rates, response duration, time to progression, and OS as shown in Table 2.

Table 2.

Efficacy Results in Patients with Small Cell Lung Cancer Sensitive to First-Line Chemotherapy in Study 090

Complete response rate
  • Partial response rate24% (16% to 32%)
  • 0%
  • 24%Response duration a(months)
  • Median (95% CI)3.3 (3.0 to 4.1)Median (95% CI)
  • Hazard ratio (95% CI)Median (95% CI)
  • Hazard ratio (95% CI)

    Parameter

    Topotecan

    (n = 107)

    CAV b

    (n = 104)

    Overall response rate (95% CI)

    18% (11% to 26%)

    1%

    17%

    3.5 (3.0 to 5.3)

    Time to progression (months)

    3.1 (2.6 to 4.1)

    2.8 (2.5 to 3.2)

    0.92 (0.69 to 1.22)

    Overall survival (months)

    5.8 (4.7 to 6.8)

    5.7 (5.0 to 7.0)

    1.04 (0.78 to 1.39)

    Abbreviations: CI = confidence interval.

    aThe calculation for duration of response was based on the interval between first response and time to progression.

    bCAV = cyclophosphamide, doxorubicin and vincristine.

    The median time to response was similar in both arms: topotecan 6 weeks (2.4 weeks to 3.6 months) versus CAV 6 weeks (5.1 weeks to 4.2 months).

    Changes on a disease-related symptom scale are presented in Table 3. It should be noted that not all patients had all symptoms, nor did all patients respond to all questions. Each symptom was rated on a 4-category scale with an improvement defined as a change in 1 category from baseline sustained over 2 cycles. Limitations in interpretation of the rating scale and responses preclude formal statistical analysis.

    Table 3.

    Symptom Improvement ain Patients with Small Cell Lung Cancer in Study 090

    Symptom

    Topotecan

    (n = 107)

    CAV c

    (n = 104)

    n b

    %

    n b

    %

    Shortness of breath

    68

    28

    61

    7

    Interference with daily activity

    67

    27

    63

    11

    Fatigue

    70

    23

    65

    9

    Hoarseness

    40

    33

    38

    13

    Cough

    69

    25

    61

    15

    Insomnia

    57

    33

    53

    19

    Anorexia

    56

    32

    57

    16

    Chest pain

    44

    25

    41

    17

    Hemoptysis

    15

    27

    12

    33

    aDefined as improvement sustained over at least 2 cycles compared with baseline.

    bNumber of patients with baseline and at least 1 post-baseline assessment.

    cCAV = cyclophosphamide, doxorubicin and vincristine.

    Single-Arm Trials

    Topotecan was also studied in 3 open-label, non-comparative trials (Studies 014, 092 and 053) in a total of 319 patients with recurrent or progressive SCLC after treatment with first-line chemotherapy. In all 3 trials, patients were stratified as either sensitive (responders who then subsequently progressed greater than or equal to 90 days after completion of first-line therapy) or refractory (no response to first-line chemotherapy or who responded to first-line therapy and then progressed within 90 days of completing first-line therapy). Response rates ranged from 11% to 31% for sensitive patients and 2% to 7% for refractory patients. Median time to progression and median survival were similar in all 3 trials and the comparative trial.

    15 references

    1. 1.OSHA Hazardous Drugs. OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html.

    16 how supplied/storage and handling

    Topotecan Injection is supplied in 4 mg/4 mL (1 mg/mL, topotecan free base) single-dose vials. Each vial contains 4 mL of the sterile, clear, yellow to yellow-green solution.

    NDC 67457-662-05 (Package of 1 single-dose vial)

    Store refrigerated between 2 and 8C (36 and 46F) in the original carton to protect from light. Discard unused portion.

    Topotecan Injection is a cytotoxic drug. Follow applicable handling and disposal procedures. 1

    17 patient counseling information

    Myelosuppression

    Inform patients that topotecan decreases blood cell counts such as white blood cells, platelets, and red blood cells. Advise patients to notify their healthcare provider promptly for fever, other signs of infection, or bleeding [see Warnings and Precautions (5.1)].

    Interstitial Lung Disease (ILD)

    Inform patients of the risks of severe ILD. Advise patients to contact their healthcare provider immediately to report new or worsening respiratory symptoms [see Warnings and Precautions (5.2)].

    Embryo-Fetal Toxicity

    Advise females of reproductive potential and males with female partners of reproductive potential of the potential risk to a fetus. Advise women to contact their healthcare provider if they become pregnant, or if pregnancy is suspected during treatment with Topotecan Injection [see Warnings and Precautions (5.4), Use in Specific Populations (8.1, 8.3)].

    Advise females of reproductive potential to use effective contraception during treatment with Topotecan Injection and for 6 months after the last dose [see Use in Specific Populations (8.1, 8.3)].

    Advise males with a female sexual partner of reproductive potential to use effective contraception during treatment with Topotecan Injection and for 3 months after the last dose [see Use in Specific Populations (8.1, 8.3), Nonclinical Toxicology (13.1)].

    Lactation

    Advise women to discontinue breastfeeding during treatment with Topotecan Injection and for at least 1 week after the last dose [see Use in Specific Populations (8.2)].

    Infertility

    Advise male and female patients of the potential risk for impaired fertility [see Use in Specific Populations (8.3), Nonclinical Toxicology (13.1)].

    Asthenia and Fatigue

    Advise patients that topotecan may cause asthenia or fatigue. These symptoms may impair the ability to safely drive or operate machinery.

    Manufactured for:

    Mylan Institutional LLC

    Rockford, IL 61103 U.S.A.

    Manufactured by:

    Mylan Laboratories Limited

    Bangalore, India

    MARCH 2020

    Ingredients and appearance - Product information

    Topotecan injection, solution, concentrate- Topotecan

    Product information

    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC: 67457-662
    Route of Administration Intravenous

    Active Ingredient/Active Moiety

    Ingredient Name Strength
    Topotecan hydrochloride ( UNII: 956S425ZCY)( Topotecan - UNII: 7M7YKX2N15 ) 1 mgin 1 mL

    Inactive Ingredients

    Ingredient Name Code
    Tartaric acid ( UNII: W4888I119H)
    Hydrochloric acid ( UNII: QTT17582CB)
    Sodium hydroxide ( UNII: 55X04QC32I)
    Water ( UNII: 059QF0KO0R)

    Product Characteristics

    Marketing Information

    Marketing Category Application Number or Monograph Citation Territorial Authority Marketing Start Date
    ANDA ANDA206074 USA

    Labeler - Mylan Institutional LLC( 790384502)

    Package/label principal display panel

    NDC 67457-662-05

    Topotecan Injection

    4 mg/4 mL (1 mg/mL)

    Must Dilute Before Intravenous Infusion

    CAUTION: CYTOTOXIC AGENT

    Discard unused portion

    Sterile

    Mylan

    Rx only

    Single-Dose Vial